北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 期刊论文
学科主题: 临床医学
题名:
分子分型及动态增强磁共振成像对乳腺癌新辅助治疗疗效的预测和评价
其他题名: A study on the predictive and evaluational value of molecular subtypes and dynamic contrast-enhanced magnetic resonance imaging of neoadjuvant chemotherapy for breast cancer
作者: 刘文清; 叶京明; 徐玲; 刘倩; 赵建新; 段学宁; 刘荫华
关键词: 乳腺肿瘤 ; 肿瘤辅助疗法 ; 治疗结果 ; 磁共振成像 ; Breast neoplasms ; Neoadjuvant therapy ; Treatment outcome ; Magnetic resonance imaging
刊名: 中华外科杂志
发表日期: 2013
DOI: 10.3760/cma.j.issn.0529-5815.2013.08.010
卷: 51, 期:8, 页:706-709
收录类别: 中国科技核心期刊 ; 中文核心期刊 ; CSCD
文章类型: Journal Article
摘要: 目的 前瞻性研究分子分型及动态增强MRI对乳腺癌新辅助治疗疗效的预测和评价价值.方法 选择2010年1月至2011年12月实施新辅助治疗并完成R0切除手术的79例乳腺癌患者,均为女性,年龄28 ~67岁,中位年龄48岁;其中Luminal A型6例,Luminal B型42例,HER-2阳性型14例,三阴型17例.研究入组患者动态增强MRI评价与病理疗效评价间的关系,分析分子分型及动态增强MRI对新辅助治疗疗效的预测和评价作用.结果 新辅助治疗临床有效率为83.5%(66/79),病理有效率为79.7%(63/79).79例患者中27例获得病理完全缓解(34.2%),其中Luminal B型12例(28.6%,12/42),HER-2阳性型5例(5/14),三阴型10例(10/17).分子分型与病理完全缓解具有统计学相关性(P =0.039).动态增强MRI临床疗效评价与病理疗效评价间有统计学相关性(r =0.432,P=0.000).结论 分子分型对乳腺癌新辅助治疗疗效具有预测价值,动态增强MRI检查与新辅助治疗后组织病理疗效评价具有相关性,有助于新辅助治疗疗效评价. Objective To investigate the predictive value of molecular subtypes and the evaluational value of dynamic contrast-enhanced MRI of neoadjuvant chemotherapy for breast cancer.Methods From January 2010 to December 2011,the 79 patients diagnosed as primary invasive breast cancer,having received 6 cycles of neoadjuvant chemotherapy and finished the mastectomy or the breast conserving surgery entered this study.A total of 79 patients participated in this prospective study.There were 6 (7.6%) luminal A cases,42 (53.2%) luminal B cases,14 HER-2 (17.7%) positive cases and 17 (21.5%) triple negative cases.The associations between molecular subtypes and clinical response as well as the pathological response were analyzed.The predictive value of molecular subtypes for the neoadjuvant chemotherapy was studied.Results Clinical effective rate was 85.3% (66/79).There was no statistical correlation between molecular subtypes and clinical effective rate.Pathologic effective rate was 79.7% (63/79).There was no statistical correlation between molecular subtypes and pathologic effective rate.Twenty-seven case achieved pathologic complete remission (pCR) in all the patients.No case achieved pCR in the patients classified as Luminal A.Twelve cases (28.6%,12/42) achieved pCR in the luminal B patients.Five cases (5/14) achieved pCR in the HER-2 overexpression patients.Ten cases (10/17) achieved pCR in the triple-negative patients.There was a statistical correlation between the molecular subtypes and the pCR rate (P = 0.039),and between clinical evaluation by dynamic contrast-enhanced MRI and evaluation of pathological response (r =0.432,P = 0.000).Conclusions Molecular subtypes and dynamic contrast-enhanced MRI have a good value of predicting and evaluating the response of neoadjuvant chemotherapy on breast cancer.
语种: 中文
原文出处: 查看原文
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/48579
Appears in Collections:北京大学第一临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 100034,北京大学第一医院乳腺疾病中心

Recommended Citation:
刘文清,叶京明,徐玲,等. 分子分型及动态增强磁共振成像对乳腺癌新辅助治疗疗效的预测和评价[J]. 中华外科杂志,2013,51(8):706-709.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[刘文清]'s Articles
[叶京明]'s Articles
[徐玲]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[刘文清]‘s Articles
[叶京明]‘s Articles
[徐玲]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace